Oral diabetes medication and risk of dementia in elderly patients with type 2 diabetes
Diabetes Research and Clinical Practice Aug 19, 2019
Kim JY, Ku YS, Kim HJ, et al. - Researchers carried out a population-based cohort study to investigate the impact of oral diabetes medication on the risk of dementia in the elderly using Korean National Health Insurance claims data from 2002 to 2013. The study sample consisted of individuals aged 60 years or older with and without type 2 diabetes. They further divided new-onset type 2 diabetes patients into oral diabetes medication and no-medication groups. Over 11 years of follow-up, 56,587 of 278,290 patients with type 2 diabetes developed dementia. In combination therapy groups, association with a lower risk of dementia was noticeable. Sulfonylurea, metformin and dipeptidyl peptidase 4 inhibitor group exhibited a markedly lower risk of dementia. Overall, in patients with type 2 diabetes, the use of oral diabetes medication considerably reduced the risk of dementia.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries